Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
about
Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.The enhanced pre- and postnatal study for nonhuman primates: update and perspectives.The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.Parallels in sources of trauma, pain, distress, and suffering in humans and nonhuman animals.Points to Consider in Designing and Conducting Juvenile Toxicology Studies.An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts.Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypesPlacental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis.Use of Thymidine Kinase Recombinant Adenovirus and Ganciclovir Mediated Mouse Liver Preconditioning for Hepatocyte Xenotransplantation.Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.
P2860
Q37902619-588CB1C0-DFE6-4CDC-8970-B4B3DA92F34BQ37947551-7708515F-3C1B-45B9-8975-EBBA7171CFB6Q37978260-22C737BF-623A-4234-982C-3507F8B168E7Q37986126-298CB161-1715-4815-8BB7-CF5EF92AD0D0Q37994716-B6029EA7-7474-463F-B231-16CAB00CEFADQ38014971-521955A9-C119-4A71-8667-059806943E8DQ38688227-6E24B1CB-BF1F-43A3-878D-BD8CFB644D2AQ38803301-92A9973E-8AD1-45CE-914E-1FAA1C4237A3Q38846742-C2352C28-2B58-401E-BEF6-378BDD9CA058Q40084188-6B872FF9-5AE9-43CC-A8EA-A970A885511EQ42366290-B406E708-EFF7-4DA7-9853-5E61C34A73F9Q43583667-0F47356C-798A-453C-A18A-658BB9298666Q45861742-08321781-0978-4597-B970-400054AFA140Q46608363-76012A93-A8F7-4E54-B63F-983821571BF6
P2860
Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developmental toxicity testing ...... erience and future directions.
@en
Developmental toxicity testing ...... erience and future directions.
@nl
type
label
Developmental toxicity testing ...... erience and future directions.
@en
Developmental toxicity testing ...... erience and future directions.
@nl
prefLabel
Developmental toxicity testing ...... erience and future directions.
@en
Developmental toxicity testing ...... erience and future directions.
@nl
P2860
P356
P1476
Developmental toxicity testing ...... erience and future directions.
@en
P2093
Gerhard F Weinbauer
Pauline L Martin
P2860
P304
P356
10.1177/1091581810378896
P577
2010-10-06T00:00:00Z